メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ

Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: An international pooled analysis

  • M. Constanza Camargo
  • , Woo Ho Kim
  • , Anna Maria Chiaravalli
  • , Kyoung Mee Kim
  • , Alejandro H. Corvalan
  • , Keitaro Matsuo
  • , Jun Yu
  • , Joseph J.Y. Sung
  • , Roberto Herrera-Goepfert
  • , Fernando Meneses-Gonzalez
  • , Yuko Kijima
  • , Shoji Natsugoe
  • , Linda M. Liao
  • , Jolanta Lissowska
  • , Sung Kim
  • , Nan Hu
  • , Carlos A. Gonzalez
  • , Yashushi Yatabe
  • , Chihaya Koriyama
  • , Stephen M. Hewitt
  • Suminori Akiba, Margaret L. Gulley, Philip R. Taylor, Charles S. Rabkin

研究成果: ジャーナルへの寄稿学術論文査読

抄録

Background and objective: About 9% of gastric carcinomas have Epstein-Barr virus (EBV) in the tumour cells, but it is unclear whether viral presence influences clinical progression. We therefore examined a large multicentre case series for the association of tumour EBV status with survival after gastric cancer diagnosis, accounting for surgical stage and other prognostic factors. Methods: We combined individual-level data on 4599 gastric cancer patients diagnosed between 1976 and 2010 from 13 studies in Asia (n=8), Europe (n=3), and Latin America (n=2). EBV positivity of tumours was assessed by in situ hybridisation. Mortality HRs for EBV positivity were estimated by Cox regression models stratified by study, adjusted for distributions of sex (71% male), age (mean 58 years), stage (52% tumour-node-metastasis stages III or IV), tumour histology (49% poorly differentiated, 57% Lauren intestinal-type), anatomic subsite (70% non-cardia) and year of diagnosis. Variations by study and continent were assessed using study-specific HRs for EBV positivity. Results: During median 3.0 years follow-up, 49% of patients died. Stage was strongly predictive of mortality, with unadjusted HRs (vs stage I) of 3.1 for stage II, 8.1 for stage III and 13.2 for stage IV. Tumour EBV positivity was 8.2% overall and inversely associated with stage (adjusted OR: 0.79 per unit change). Adjusted for stage and other confounders, EBV positivity was associated with lower mortality (HR, 0.72; 95% CI 0.61 to 0.86), with low heterogeneity among the study populations (p=0.2). The association did not significantly vary across patient or tumour characteristics. There was no significant variation among the three continent-specific HRs (p=0.4). Conclusions: Our findings suggest that tumour EBV positivity is an additional prognostic indicator in gastric cancer. Further studies are warranted to identify the mechanisms underlying this protective association.

本文言語英語
ページ(範囲)236-243
ページ数8
ジャーナルGut
63
2
DOI
出版ステータス出版済み - 02-2014
外部発表はい

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

  1. SDG 3 - すべての人に健康と福祉を
    SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

  • 消化器病学

フィンガープリント

「Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: An international pooled analysis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル